InvestorsHub Logo
Followers 840
Posts 120475
Boards Moderated 18
Alias Born 09/05/2002

Re: None

Monday, 06/04/2018 11:50:03 AM

Monday, June 04, 2018 11:50:03 AM

Post# of 6217
VXRT -17% on failed phase-2 in condyloma:

https://finance.yahoo.com/news/vaxart-reports-topline-results-phase-110000569.html

With respect to the primary efficacy endpoint, 30.6% of patients in the teslexivir group completely cleared baseline condyloma by week 16, compared to 23.3% of patients in the placebo group. The difference was not statistically significant.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VXRT News